Diligence memo · auto-generated · as of July 2, 2026
Pernix Therapeutics Holdings, Inc.
Pernix Therapeutics Holdings, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Pernix Therapeutics Holdings, Inc. operates in Pharmaceuticals, based in The Woodlands.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Pernix Therapeutics Holdings, Inc. has raised $34M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $34M on 2012-12-31.
Most recent recorded round closed around 2012-12-31.
Valuation (modeled)modeled
Provath models Pernix Therapeutics Holdings, Inc. at approximately $1.2B (range $71M–$4.4B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.56× the median modeled value of Series B Pharmaceuticals companies in 2010–2012 (47 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 13.5 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 76% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 90% of those peers.
Closest niche peers: Celator Pharmaceuticals Inc, Kythera Biopharmaceuticals Inc, Palatin Technologies Inc, CEBIX Inc, Topica Pharmaceuticals Inc.
Peoplefiled
7 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.